The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.
about
Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine PathologyHeadache management: pharmacological approachesStimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)Acute Migraine Treatment in Adults.Diagnosis and Treatment of Childhood Migraine.Clinically significant psychotropic drug-drug interactions in the primary care setting.Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study.Bipolar affective disorder and migraine.Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.Complementary and alternative medicine use among adults with migraines/severe headaches.A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room.Clinically significant drug interactions with newer antidepressants.Migraine and depression comorbidity: antidepressant options.Panic disorder and migraine: comorbidity, mechanisms, and clinical implications.The pathophysiological and pharmacological basis of current drug treatment of migraine headache.Headache as a presenting feature in patients with serotonin syndrome: a case series.Sumatriptan/naproxen sodium: a review of its use in adult patients with migraine.Traditional and alternative treatments for depression: implications for migraine management.Medication overuse and chronic migraine: a critical review according to clinical pharmacology.Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review.Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice.Oral sumatriptan and almotriptan--delimiting the MAOI effect.Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.Drug-drug interactions involving antidepressants: focus on desvenlafaxine.[Serotonin syndrome and pain medication : What is relevant for practice?].Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.Treatment of headache following triptan failure after successful triptan therapy.Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome.The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats.Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome
P2860
Q26752538-18DE5C67-7883-4DFF-93C1-0D29B2B804C1Q27316751-18A4EA9A-DB29-4630-9781-D0F363D88725Q34389980-4723CC89-9E31-43F0-9842-7E3AAE5C9AD9Q34471863-5B0BCC38-0863-41C3-A28D-3BF0756FDB2FQ34541963-1D7D2207-CB5D-4E6D-BBCE-D88CF61F54CDQ35104220-E6E02DB0-60FB-49A4-AB76-1C7CD08E69B5Q35168831-E0BE7CF6-631E-48DD-B56A-1AFA0B61C071Q35977534-1B8261BE-B449-494A-9D81-EB57E7DA8AA4Q36598107-88337AD9-8E49-4EB0-BEBF-7A1F4EB1C257Q36768839-E6A17D2F-8E2F-4903-8192-56A8F4A62116Q37080223-23F193FD-3E11-45F1-B032-5CAB565C4E2AQ37968621-E62B0DD6-354D-4717-B319-AB7D2F5A3363Q38014294-EC47ED8A-DA55-4EA9-A3A0-67756ACE55E1Q38070731-61AEB4E2-250C-42B1-A512-0438BF0C151EQ38105147-B71E0D09-4CDA-4E45-B8A2-20411BB50A86Q38119391-29A9545F-D155-46B9-91B0-4CD01A505959Q38126370-225C443F-2434-417F-B1D8-CF23E68E574AQ38341758-FB12594F-8681-4681-8E8F-968D18C8439BQ38509398-07493D14-7067-42AD-9B53-9E5E6054BD1CQ39048593-FA5A5470-4368-4F6D-A2CF-DE509288C35AQ44728902-F8A3DE7B-A006-4DFE-B4CC-596EBAA999F2Q46045347-98389DBD-AD86-4024-AA76-4C3FAC23E476Q49873285-3F72A91D-4251-44C6-95A1-003667CB4F52Q52369980-ACF12A30-E455-4EA0-B795-A233CADCBB41Q52867855-78962697-2318-4033-BA51-A4524D3477EBQ53091817-27194B60-8E83-4F25-811B-9E14F54B290AQ53510678-C879A7D5-9975-4E1D-88E5-3B5D3D25205DQ53674412-6C28C428-8B98-43BE-B2BD-FE007CDA33C9Q55276916-C8713899-C389-453D-A1F8-6AEED50A5557Q55954464-40148326-95D0-4CE5-8026-A11DA4571FE9
P2860
The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The FDA alert on serotonin syn ...... adache Society position paper.
@en
The FDA alert on serotonin syn ...... adache Society position paper.
@nl
type
label
The FDA alert on serotonin syn ...... adache Society position paper.
@en
The FDA alert on serotonin syn ...... adache Society position paper.
@nl
prefLabel
The FDA alert on serotonin syn ...... adache Society position paper.
@en
The FDA alert on serotonin syn ...... adache Society position paper.
@nl
P2093
P921
P1433
P1476
The FDA alert on serotonin syn ...... adache Society position paper.
@en
P2093
Christina Sun-Edelstein
Gretchen E Tietjen
Robert E Shapiro
P304
P356
10.1111/J.1526-4610.2010.01691.X
P577
2010-06-01T00:00:00Z